Madrigal Pharmaceuticals Surges 3.94% on $240M Volume Spike Climbs to 362nd in Market Trading Rank

Madrigal Pharmaceuticals (MDGL) surged 3.94% on August 21, 2025, with a trading volume of $240 million, marking a 98.02% increase from the previous day’s activity. The stock ranked 362nd in trading volume among listed equities, reflecting heightened investor interest.

The company announced the grant of 6,940 time-based restricted stock units to 11 new non-executive employees under its 2025 Inducement Plan. The awards, approved by Madrigal’s independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4), are designed to incentivize employment retention. The units vest in four equal annual installments, contingent on continued employment, signaling a strategic focus on long-term talent development.

Madrigal’s ongoing Phase 3 trial for Rezdiffra, its FDA- and EU-approved MASH treatment, remains a key catalyst for growth. The drug’s potential expansion into compensated cirrhosis (F4c) could broaden its market reach, though near-term progress depends on trial outcomes and regulatory developments.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The CAGR was 6.98%, with a maximum drawdown of 15.59% during the backtest period. The strategy demonstrated steady growth over time, making it a robust choice for investors seeking consistent returns. However, the significant drawdown in mid-2023 highlights the importance of risk management in high-volume trading strategies.